FDA Prioritizes Reviews Of Opioid Overdose ANDAs

 
• By Aidan Fry

Opioid overdose treatments containing naloxone or nalmefene are now eligible for expedited ANDA review in a bid by the FDA to improve patient access.

May 26, 2017-ogden Utah USA: naloxone and narcan nasal sprays are now available over the counter to prevent drug overdoses. - Illustration
Narcan is among the reference brands for which the FDA is accelerating ANDA review • Source: Shutterstock

More from Regulation

More from Policy & Regulation